RATIONALE: Dose-response studies are required showing optimal efficacy of an allergen extract in AIT. The allergen exposure chamber (AEC) is an outcome parameter accepted by the regulatory authorities for this purpose. METHODS: 193 (FAS) patients with grass pollen allergic rhinitis/ rhinoconjunctivitis were treated in a DBPC study with 4 concentrations of 1000, 3000, 5000 and 8000 DPP/ml allergen extract over 20 weeks in Germany, Poland and Spain. A 1-day build-up phase of the corresponding extract was followed by 5 maintenance doses in 3-4 weeks intervals. Patients were exposed to 4000 Dactylis grains/m 3 in an AEC at baseline and after AIT. Primary endpoint was the reduction of the total nasal symptom score assessed in the AEC before and after treatment with depigmented polymerized Phleum extract vs. placebo. Secondary parameters were specific IgE, IgG1 and IgG4, Phleum component resolved diagnosis and safety. RESULTS: Statistically significant differences were found between 1000 DPP/mL vs 8000 DPP/mL treatment groups (p 5 0.0249) for the FAS population. The immunological analysis showed statistically significant increases in a dose-dependent manner in all active groups for the sIgE, sIgG1 and IgG4. Severe local reactions occurred only in few patients. Regarding systemic reactions, 43.1% of patients receiving placebo and 51.1 % patients in the highest concentration developed WAO grade I or II systemic reactions. One systemic reaction in the 5000 DPP/ml group was a grade III reaction. CONCLUSIONS: A dose-dependent immunological response was observed with the depigmented polymerized Phleum extract up to 8000 DPP/ml. No safety concerns were detected at any of the concentrations evaluated.
Hospital Regional Universitario M alaga -IBIMA, M alaga, Spain, 4 Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA, M alaga, Spain. RATIONALE: Similarly to allergic rhinitis (AR), many local allergic rhinitis (LAR) individuals report bronchial symptoms suggestive of asthma. In a follow-up study in LAR patients, bronchial symptoms increased from 18.4% to 24.4% during the first five years and to 30.7% after ten years. Though these findings indicate that close to 30% of subjects with LAR will have symptoms of asthma at some point of their evolution, this aspect remains to be analysed in detail. The aim was to evaluate the presence of asthma in LAR patients based on validated objective methods. METHODS: Patients with LAR, non-allergic rhinitis (NAR), AR, and healthy controls (HC) were included. All patients had perennial rhinitis and bronchial symptoms suggestive of asthma (mild-moderate) > _ 2 years. Airways hyperresponsiveness was evaluated by methacholine challenge test in all participants RESULTS: Sixty-seven patients (29 with LAR, 20 with non-allergic rhinitis (NAR), 18 with allergic rhinitis (AR)), and 8 healthy controls (HC) were included. Subjects were mostly non-smokers, with a similar median dose of inhaled corticosteroids in all groups. Median FEV1% in LAR group (90%) was significantly higher compared to AR (75.5%, P50.002), NAR (85%, P50.007) and HC (88%, P50.005). Fifty-two percent in the LAR group (15/29) had a positive methacholine, 60% in NAR (12/20), 83.3% in AR (15/18) and 0% in HC (0/8). The percentage of confirmed asthma was lower in LAR patients compared to AR (P50.031) and similar to NAR (P50.771), with no differences between AR and NAR (p50.155). CONCLUSIONS: Objectively confirmed asthma was less frequent in LAR compared to AR.
